Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on December 20, 2022. The company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, MA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing status update rather than financial performance data.
Material Changes
The primary material event is a notice of non-compliance received from the Nasdaq Listing Qualifications Department. The company failed to meet the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $5,000,000. This deficiency was based on the MVPHS calculated over the 31 consecutive business days from November 4, 2022, to December 19, 2022.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted the company a 180-calendar-day compliance period, ending on June 19, 2023, to regain compliance.
- Regaining Compliance: To satisfy the requirement, the company's MVPHS must close at or above $5,000,000 for a minimum of 10 consecutive business days within the compliance period.
- Delisting Risk: If the company fails to regain compliance by June 19, 2023, it may face delisting from the Nasdaq Global Market.
- Current Status: The notice is a notification of deficiency only and has no immediate effect on the listing or trading of the company's securities.
- Management Action: Management intends to monitor the MVPHS and evaluate available options to regain compliance during the allotted period.
Key Facts for Investor Verification
- Verify the current Market Value of Publicly Held Shares (MVPHS) to assess the gap to the $5,000,000 threshold.
- Monitor the company's stock price and share count daily to track progress toward the 10-day consecutive compliance requirement.
- Review previous 8-K filings (October 14, 2022, and November 25, 2022) referenced in the text for historical context on listing deficiencies.
- Watch for announcements regarding potential capital raises or reverse stock splits as potential strategies to regain compliance before the June 19, 2023 deadline.